PWMG
TRDA icon

Private Wealth Management Group’s Entrada Therapeutics TRDA Stock Holding History

Private Wealth Management Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56K Hold
212
– – ﹤0.01% 1213
2026
Q1 		$2.68K Hold
212
– – ﹤0.01% 983
2025
Q4 		$2.18K Hold
212
– – ﹤0.01% 1056
2025
Q3 		$1.23K Buy
+212
New +$1.24K ﹤0.01% 1233

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Private Wealth Management Group's TRDA Position: Q2 2026 in Review

Private Wealth Management Group held its Entrada Therapeutics (TRDA) position steady in Q2 2026 at 212 shares worth $1.56K. The position accounts for ﹤0.01% of the portfolio, ranked #1213.

Private Wealth Management Group first reported a position in TRDA in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.68K in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Private Wealth Management Group held 212 shares of Entrada Therapeutics worth $1.56K as of Q2 2026.
  • Private Wealth Management Group left its Entrada Therapeutics share count unchanged in Q2 2026.
  • Entrada Therapeutics made up ﹤0.01% of Private Wealth Management Group's portfolio in Q2 2026, its #1213 holding.
  • Private Wealth Management Group first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Private Wealth Management Group's Entrada Therapeutics position peaked at $2.68K in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Private Wealth Management Group's 13F filing for Q2 2026, filed 27 Jul 2026.